Drug Approval | March 28, 2024
Biocon to obtain approval for diabetes drug, Liraglutide in UK
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
Cipla will be responsible for the distribution of Sanofi India's six CNS brands including Frisium
Combination shows consistent benefit across prespecified post-progression outcomes
Hepatitis B infects over 40 million people in India
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
The pilot plant is focused on scaling up beverage production and will support applications
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Sen spent a decade with Biocon and held various key roles,
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
Subscribe To Our Newsletter & Stay Updated
